Increased levels of OPN were also observed in the cerebrospinal fluid (CSF) of MS patients and correlate with cognitive impairment, suggesting OPN may be a key player in the dysregulated bone-brain axis in MS and may serve as a biomarker of disease progression (Wen et al., 2012). The gene discussed is SPP1; the disease is myeloid sarcoma.